Clinical Trial: Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm

Brief Summary: Delivery of HFA albuterol through an antistatic valved holding chamber (VHC) will improve bronchodilator response during nocturnal bronchospasm.

Detailed Summary:
Sponsor: University of Florida

Current Primary Outcome:

• Y=100([FEV1 at 1 Puffs-FEV1 at 4AM)/FEV1@4AM] Difference Period 2 Minus Period 1. [ Time Frame: fifteen minutes after 1 puff of albuterol ]
  (Percent improvement in FEV1 Post Dose for Period 2 over 4AM Baseline value) less (Percent improvement in FEV1 Post Dose for Period 1 over 4AM Baseline value) when 1 Puff go into chamber
• Y=100([FEV1 at 2 Puffs-FEV1 at 4AM)/FEV1@4AM] Difference Period 2 Minus Period 1. [ Time Frame: 15 minutes after 2 puffs of albuterol ]
  (Percent improvement in FEV1 Post Dose for Period 2 over 4AM Baseline value) less (Percent improvement in FEV1 Post Dose for Period 1 over 4AM Baseline value) when 2 Puffs go into chamber
• Y=100([FEV1 at 4 Puffs-FEV1 at 4AM)/FEV1@4AM] Difference Period 2 Minus Period 1. [ Time Frame: fifteen minutes after 4 puffs of albuterol ]
  (Percent improvement in FEV1 Post Dose for Period 2 over 4AM Baseline value)less (Percent improvement in FEV1 Post Dose for Period 1 over 4AM Baseline value) when 4 Puffs go into chamber

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of Florida

Dates:
Date Received: April 23, 2010
Date Started: May 2008
Date Completion:
Last Updated: May 14, 2012
Last Verified: May 2012